Results 1 to 10 of about 9,937 (184)

Quantitation of platelet‐specific autoantibodies in platelet eluates of ITP patients measured by a novel ELISA using the purified glycoprotein complexes GPIIb/IIIa and GPIb/IX as antigens [PDF]

open access: bronzeBritish Journal of Haematology, 1997
Immune thrombocytopenic purpura (ITP) is a disorder caused by anti‐platelet autoantibodies (Ab), most of which are directed against epitopes on platelet membrane glycoprotein complexes GPIIb/IIIa and GPIb/IX. To detect platelet Ab, reliable techniques, such as MAIPA or immunobead assay, have been developed.
M, Hurlimann-Forster   +2 more
openaire   +3 more sources

Investigation of interaction of human platelet membrane components with anticoagulant drugs Abciximab and Eptifibatide. [PDF]

open access: yesFolia Histochemica et Cytobiologica, 2011
Abciximab (Abci) and eptifibatide (Epti) are antiaggregate drugs which may reduce thrombotic complications in acute coronary syndromes. The aim of this work was the investigation of the interaction between the phospholipid-GPIIb/IIIa glycoprotein complex
Anna Sankiewicz   +2 more
doaj   +3 more sources

Antiplatelet antibody predicts platelet desialylation and apoptosis in immune thrombocytopenia

open access: yesHaematologica, 2022
Immune thrombocytopenia (ITP) is a bleeding disorder caused by dysregulated B- and T- cell functions, which lead to platelet destruction. A well-recognized mechanism of ITP pathogenesis involves anti-platelet and anti-megakaryocyte antibodies ...
Shiying Silvia Zheng   +6 more
doaj   +1 more source

Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist

open access: yesTH Open, 2021
Introduction Prehospital therapy of ST-elevation myocardial infarction (STEMI) with αIIbβ3 antagonists improves clinical outcomes, but they are difficult to use in prehospital settings.
Ohad S. Bentur   +5 more
doaj   +1 more source

Primary percutaneous transluminal coronary angioplasty in the acute infarction of the right ventricle [PDF]

open access: yesVojnosanitetski Pregled, 2003
Background. Predilection site for the acute myocardial infarction of the right ventricle, (AMI-RV) is the upper third of the right coronary artery and for this reason such an infarction is followed by numerous complications, primarily by conduction ...
Gligić Branko   +7 more
doaj   +1 more source

Identification of one novel pathogenic ITGB3 mutation and two known mutations in two Chinese pedigrees with hereditary Glanzmann thrombasthenia

open access: yesPlatelets, 2020
Glanzmann thrombasthenia (GT) is an inherited disorder of platelet aggregation resulting from quantitative and/or qualitative abnormalities of the glycoprotein IIb/IIIa complex.
Zhengjing Lu   +7 more
doaj   +1 more source

Platelet surface marker analysis by mass cytometry

open access: yesPlatelets, 2020
Mass cytometry is a next generation flow cytometry technology which analyzes cells one at a time (up to 1000/sec) using mass spectrometry to detect probes labeled with rare-earth metals.
Thomas A. Blair, Andrew L. Frelinger
doaj   +1 more source

Significant correlation of angiotensin converting enzyme and glycoprotein IIIa genes polymorphisms with unexplained recurrent pregnancy loss in north of Iran [PDF]

open access: yes, 2016
Background: Spontaneous abortion is considered as the most complex problem during pregnancy. Thrombophilia is resumed as a cause of recurrent pregnancy loss (RPL). Glycoprotein IIIa (GPIIIa) gene is involved in thrombosis and abortion.
Farazmandfar, T.   +2 more
core   +1 more source

Newer agents in antiplatelet therapy: a review. [PDF]

open access: yes, 2012
Antiplatelet therapy remains the mainstay in preventing aberrant platelet activation in pathophysiological conditions such as myocardial infarction, ischemia, and stroke.
Holinstat, Michael, Yeung, Jennifer
core   +3 more sources

Estudo experimental do uso de um antagonista do receptor da glicoproteína IIb/IIIa das placentas na prevenção de tromboses em microanastomoses vasculares An experimental study on the use of an antagonist of the platelet glycoprotein IIb/IIIa receptor in the prevention of thrombosis in vascular microanastomoses

open access: yesActa Ortopédica Brasileira, 2000
O autor comparou, experimentalmente, a eficácia da droga abciximab, um antagonista do receptor da glicoproteína IIb/IIIa das plaquetas, na prevenção da trombose nas microanastomoses arteriais em ratos Wistar.
Márcio Issamu Oide
doaj   +1 more source

Home - About - Disclaimer - Privacy